医学分子生物学杂志 ›› 2021, Vol. 18 ›› Issue (4): 321-324.doi: 10.3870/j.issn.1672-8009.2021.04.013

• 论著 •    

GLP-1 受体激动剂类药物 ( GLP-1 RA) 2 型糖尿病治疗中的研究进展 

  

  1. 1南京农业大学生命科学学院 南京市, 210095 2南京医科大学基础医学院生物化学与分子生物学系 南京市, 211166
  • 出版日期:2021-07-31 发布日期:2025-11-10
  • 基金资助:
    国家自然科学基金青年基金( No. 82000738);江苏省自然科学基金青年基金(No. BK20200670)

Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) in the Treatment of Type 2 Diabetes Mellitus 

  1. 1The School of Life Science, Nanjing Agricultural University, Nanjing, 210095, China 2The School of Basic Medicine, the Department of Biochemistry, Nanjing Medical University, Nanjing, 211166, China
  • Online:2021-07-31 Published:2025-11-10

摘要: 2 型糖尿病 (type 2 diabetes mellitus, T2DM) 是以高血糖症高脂血症为主要特征的慢性代谢性疾病持续的高血糖高血脂会导致机体继发多种重要器官的并发症, 严重威胁人类生命健康因此, 2型糖尿病的预防与治疗, 已经成为医药研发工作者面临的巨大挑战胰高血糖素样肽-1 ( GLP-1) 是回肠内分泌细胞分泌的一种脑肠肽, 其受体目前主要作为 2 型糖尿病降糖药物作用的靶点。 GLP-1 受体激动剂类药物 (GLP-1 RA) 是药企等研发机构近年研究的热点, 已被证明在 2 型糖尿病的治疗中发挥着积极有效的作用, 文章总结了该类药物近几年的研究进展

关键词:

GLP-1 受体激动剂, 2 型糖尿病, 药物治疗

Abstract: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized byhyperglycemia and hyperlipidemia. Persistent elevated blood glucose and lipids cause complications in various important organs and tissues, which seriously threaten human life and health. Therefore, the prevention and treatment of T2DM has become a huge challenge faced by pharmaceutical research and development workers. Glucagon-like peptide-1 (GLP-1) is a brain-gut peptide secreted by endocrine cells in the ileum. Its receptor is currently used as a target for anti-T2DM drugs. GLP-1 receptor agonists (GLP-1RA) have been a hotspot in research and development institutions such as pharmaceutical companies in recent years, and have been proven to play an active and effective role in the treatment of T2DM. This article summarizes the research progress of GLP-1RA in recent years.

Key words: GLP-1 receptor agonist, type 2 diabetes mellitus, drug therapy

中图分类号: